Innovation Drives Divergence: US FDA Drugs and Biologics Centers Follow Own Trajectories

 
• By Bridget Silverman
  
Pink Sheet Perspectives
The US FDA's drugs and biologics centers increasingly follow different regulatory routes as the agency accommodates the growing regenerative medicine pipeline. (Shutterstock)

More from Pink Sheet Perspectives

More from CDER Novel Approvals